NovoSeven HI 2 mg syringe for intravenous injection

NovoSeven HI 2 mg syringe for intravenous injection (YJ code: 6343434D7026, 2 mg 2 mL x 1 bottle (with dissolving solution)), manufactured by Novo Nordisk Pharma, contains Eptacog alpha (activated) (genetical recombination). This recombinant factor VIIa is indicated for the treatment and prevention of bleeding in patients with congenital hemophilia with inhibitors, acquired hemophilia, congenital FVII deficiency, and Glanzmann’s thrombasthenia.